Evidence map›Paper›PMID 34072863›Full record

ArticleCancers2021

Who's Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma.

Sandra N Freiberger, Patrick Turko, Martin Hüllner, Reinhard Dummer, Grégoire B Morand, Mitchell P Levesque, David Holzmann, Niels J Rupp

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Pathologica · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sandra N FreibergerDepartment of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-6874-9649
Patrick TurkoDepartment of Dermatology, University Hospital Zurich, 8058 Zurich, Switzerland.
Martin HüllnerFaculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
Reinhard DummerFaculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.ORCID 0000-0002-2279-6906
Grégoire B MorandFaculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.ORCID 0000-0002-6150-6772
Mitchell P LevesqueFaculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.ORCID 0000-0001-5902-9420
David HolzmannFaculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
Niels J RuppDepartment of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-7043-3456
University of Zurich · CHUniversity Hospital of Zurich · CH

Funding

Cancer League Zurich Investigation of novel marker combinations to predict response to immunotherapy in mucosal melanoma
6 · The paper itself

Abstract

Mucosal melanoma can be driven by various driver mutations in genes such as

Indexed as

disease monitoringimmunotherapymucosal melanomaoncogenic driversinonasal cancertumor heterogeneity

Identifiers

PMID34072863
PMCPMC8198298
OpenAlexW3165885083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.